Quick Answer Box
Where do you buy PT-141 in Canada in 2026? The leading domestic option is Nox Peptides, currently the only Canadian retail-facing supplier publishing both purity and endotoxin lab reports per batch. Other verified Canadian suppliers carrying PT-141 include Peptide Warehouse, Polar Peptides, Growth Guys, XPeptides, Canadian Peptides, Clinical Peptides, NCRP, Amino Pure Canada, Purity Peptides, VPeptide, and PeptidePro Canada.
PT-141 essentials:
- What it is: PT-141 (bremelanotide) is a synthetic cyclic heptapeptide, a 7-amino-acid melanocortin receptor agonist derived from alpha-melanocyte-stimulating hormone (α-MSH). The molecular formula is C₅₀H₆₈N₁₄O₁₀; the molecular weight is approximately 1025.2 Da.
- Mechanism: Binds melanocortin receptors MC3R and MC4R in the central nervous system, distinct from peripheral vascular mechanisms targeted by PDE-5 inhibitors.
- Status in Canada: Bremelanotide (FDA-approved as Vyleesi for HSDD in premenopausal women in the US) is not approved by Health Canada and doesn’t carry a Canadian Drug Identification Number (DIN). PT-141 in Canada exists strictly within the research-chemical category, sold for laboratory research use only, not for human consumption.
- Typical 2026 Canadian pricing: Approximately CAD $50-$110 per 10mg vial depending on supplier quality tier.
- Synthesis note: PT-141’s cyclic structure (lactam bridge between Asp and Lys residues) plus D-Phe substitution makes it more complex to synthesize than linear peptides, affecting pricing and quality differentiation between suppliers.
What PT-141 Actually Is — The Cyclic Heptapeptide Story
PT-141 (bremelanotide) is structurally distinct from most other research peptides on the Canadian market. Understanding the structure clarifies why pricing and quality vary so meaningfully between suppliers:
| Property | Specification |
|---|---|
| Compound name | Bremelanotide (PT-141) |
| Type | Synthetic cyclic heptapeptide (7 amino acids) |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular formula | C₅₀H₆₈N₁₄O₁₀ |
| Molecular weight | ~1025.2 Da |
| CAS number | 189691-06-3 |
| PubChem CID | 9941379 |
| Parent compound | Alpha-melanocyte-stimulating hormone (α-MSH); structurally related to Melanotan II |
| Cyclization | Lactam bridge between Asp and Lys residues |
| Health Canada status | Not approved for human use |
| FDA status (US) | Approved as Vyleesi for premenopausal HSDD (2019) |
Three structural features make PT-141 distinctive:
- The cyclic structure. The Asp-Lys cyclization requires controlled solid-phase peptide synthesis with specific protecting-group strategy. Linear peptide analogs are 30-50% cheaper to manufacture.
- The D-Phe substitution. D-amino acids cost more than L-amino acids and require careful chiral purification.
- The CNS-targeting mechanism. PT-141 binds MC3R and MC4R receptors in the hypothalamus and limbic system, distinct from how PDE-5 inhibitors work peripherally.
For Canadian buyers, the practical implication is direct: a vendor selling PT-141 at sermorelin-like prices (CAD $1-$2/mg) is almost certainly substituting a cheaper related peptide. PT-141’s synthesis difficulty creates a real price floor below which legitimate research-grade material can’t be produced.
📊 PT-141 Research Applications Driving Canadian Demand
| Research Domain | What’s Being Studied |
|---|---|
| Melanocortin receptor pharmacology | MC3R/MC4R receptor binding kinetics, downstream signaling |
| Sexual function research | CNS-mediated arousal pathways distinct from PDE-5 vascular mechanisms |
| Energy homeostasis modeling | MC4R loss-of-function is one of the most common monogenic causes of severe human obesity, PT-141 used as acute MC4R agonist in rodent feeding studies |
| Neuroinflammation research | Microglia and brain macrophages express MC1R and MC3R; melanocortin agonism shifts them toward anti-inflammatory phenotypes |
| Comparative class research | PT-141 vs. Melanotan-2 vs. other melanocortin compounds head-to-head studies |
| Blood-brain barrier penetration research | PT-141’s BBB penetration sets it apart from many peripherally acting peptides |
🎥 Watch: Melanocortin Receptor Pharmacology — How PT-141 Works
Dr. Andrew Huberman covers the major categories of peptides currently in use for therapeutic and research purposes, including melanocortin-class peptides like PT-141 and the central nervous system mechanisms that set them apart from peripherally-acting compounds.
The Canadian Regulatory Picture for PT-141 in 2026
PT-141’s regulatory situation in Canada has a unique twist worth understanding before sourcing:
| Question | Answer |
|---|---|
| Is bremelanotide approved as a drug in Canada? | No. Bremelanotide doesn’t have Health Canada approval and doesn’t carry a Canadian DIN. |
| Is bremelanotide approved as a drug elsewhere? | Yes. The FDA approved bremelanotide as Vyleesi in 2019 for premenopausal hypoactive sexual desire disorder (HSDD) in the US market. |
| Can a Canadian physician prescribe PT-141? | No. Without a Canadian DIN, no physician can legally prescribe PT-141 within the Canadian regulatory framework. Cross-border prescriptions for Vyleesi from US physicians don’t translate to a legal Canadian prescription pathway. |
| Where does PT-141 legally exist in Canada? | Strictly within the research-chemical category, sold to qualified researchers for laboratory research and in-vitro experimental use only. |
The unusual aspect: PT-141 is one of the few peptides where there is an approved drug equivalent (Vyleesi), but only outside Canadian regulatory borders. Canadian buyers face a binary: research-grade peptide retailers (legal pathway) or no legal pathway at all. Importing Vyleesi from US prescriptions creates additional regulatory complexity that varies by province and individual circumstances.
For full context on Canadian peptide regulations, review:
- 🇨🇦 Health Canada — Think twice before injecting peptides bought online (April 2026 advisory)
- 🇨🇦 Health Canada — Drug Product Database
- ⚕️ College of Physicians & Surgeons of Alberta — Unauthorized injectable peptides
- 📰 CBC News — Health Canada warns against unauthorized peptides (April 2026)
The 7-Point Verification Framework for Research-Grade PT-141
| # | Verification Signal | Why It Matters for PT-141 Specifically |
|---|---|---|
| 1 | Independent third-party COA per batch | Self-issued COAs aren’t verification, Janoshik or equivalent matters more for cyclic peptides where structure verification is harder |
| 2 | HPLC purity ≥98% | ≥99% upper-tier standard appropriate for cyclic structure |
| 3 | Mass spectrometry sequence verification | Critical for cyclic peptides, confirms the lactam bridge formed correctly, not just that the linear precursor is present |
| 4 | Endotoxin testing | Particularly relevant for CNS-targeted peptides; bacterial contamination can confound neuropharmacology research |
| 5 | Domestic Canadian shipping | Cuts out CBSA seizure risk; melanocortin compounds can attract more customs scrutiny than recovery peptides |
| 6 | Research-use-only framing | Vendors marketing direct-to-consumer for personal use are working outside the legal framework |
| 7 | Cyclization verification | Some suppliers may sell linear bremelanotide-precursor instead of properly cyclized PT-141, mass spec confirms the cyclic structure |
1. Nox Peptides — The Documentation Standard for Cyclic Peptide Research
Site: noxpeptides.ca
Standout claim: Only Canadian retail supplier publishing both purity AND endotoxin lab reports on PT-141
Best for: Researchers requiring the deepest documentation chain on a cyclic peptide where structural verification matters
Nox Peptides earns the #1 spot because PT-141’s cyclic structure raises the documentation bar above standard linear peptides. Most Canadian retailers stop at HPLC purity COAs. Nox publishes those reports plus endotoxin testing, testing typically reserved for GMP pharmaceutical manufacturing.
For PT-141 specifically, that documentation depth matters because:
- Cyclic structure verification, proper lactam bridge formation between Asp and Lys residues is what differentiates PT-141 from cheaper linear analogs
- CNS-targeted research applications, endotoxin contamination would independently trigger neuroinflammation responses, confounding melanocortin pharmacology research
- Synthesis complexity, D-Phe substitution and cyclization create more synthesis failure points than typical linear peptides
The Nox brand framing: NØX is a performance science system engineered for measurable human output, designing, synthesizing, and validating precision performance compounds with documented traceability and authorized release.
What you actually get with Nox PT-141:
- Per-batch purity reports from independent third-party lab
- Per-batch endotoxin reports, invisible on every other Canadian retailer’s COAs
- Mass spectrometry verification confirming cyclic structure
- Domestic Canadian dispatch with Canadian customer service
- Catalog adjacency, PT-141 alongside other melanocortin and CNS-targeted peptides for comparative research
Browse the PT-141 listing and per-batch lab reports at noxpeptides.ca.
2. Peptide Warehouse — Canadian Manufacturing with PT-141 Specialty
Site: peptidewarehouse.ca
Catalog focus: Made-in-Canada manufacturing with explicit positioning vs. China-imported alternatives
Peptide Warehouse positions PT-141 within their explicit “Made in Canada” framing: Peptide Warehouse is Canadian’s only seller of peptides with manufacturing facilities located in Canada. Other sellers import vials from China. With the production of the vials done in Canada, we can better control the quality and ensure the vial has the full weight of the peptide declared on the label. Many Chinese products are under-dosed and only contain a small percentage of the total peptide.
For PT-141 specifically, that under-dosing concern matters more than for simpler peptides. The cyclic structure complexity means that “PT-141” sold at extreme discount pricing may contain primarily linear bremelanotide precursor, partially-cyclized product, or related melanocortin compounds substituted for the labeled compound. Domestic Canadian manufacturing under controlled facility conditions cuts down those substitution risks.
Peptide Warehouse also explicitly publishes Health Canada warning language alongside their PT-141 product, appropriate research-use framing that lines up with regulatory expectations.
3. Polar Peptides — Detailed Cyclic Peptide Documentation
Site: polarpeptides.ca
Catalog focus: Detailed product specifications including molecular profile documentation
Polar Peptides has built a reputation around detailed product documentation, and PT-141 is one of the products where that depth particularly matters. For cyclic peptides, full sequence documentation, molecular weight specification, and reconstitution guidance are more meaningful than for simpler linear compounds because batch-level verification of the cyclic structure is harder for end-users.
Operational logistics: orders ship within 24 hours Monday-Friday from a Canadian fulfillment centre, with 2-5 business day delivery. Interac e-Transfer is accepted as the standard Canadian payment method. Per-product listings publish full molecular profiles, meaningful for researchers who want to verify they’re receiving genuinely cyclic PT-141 rather than a linear analog.
4. Growth Guys — Janoshik Public Verification
Site: growthguys.is
Catalog focus: Janoshik-verified batch testing across the catalog
Growth Guys offers PT-141 with the Janoshik Analytical batch verification standard that’s defined the Canadian peptide community quality benchmark in 2026. Janoshik’s public verification system at janoshik.com lets researchers look up specific batch results independently using a unique key, confirming the supplier’s published COA matches the actual lab report.
For PT-141 specifically, that independent verification matters more than for many other research peptides. The cyclic structure verification challenge means buyers can’t easily tell apart properly-cyclized PT-141 from improperly-synthesized alternatives without analytical infrastructure. Independent third-party lab verification is essentially the only practical defense against this substitution risk.
5. XPeptides — Canada-Specific PT-141 Specialty
Site: xpeptides.ca
Catalog focus: Canadian-domestic supplier with explicit PT-141 product positioning and Canada Post fulfillment
XPeptides offers PT-141 with explicit domestic Canadian framing: High-purity PT-141 research peptide available in Canada. Lab-tested, verified quality, and fast domestic shipping via CANADA POST. Their product description appropriately frames PT-141 within the research context: PT-141 peptide, also known as Bremelanotide, is a research peptide used in studies on melanocortin signaling, libido pathways, and neurohormonal activity. Researchers often explore PT-141 in work involving sexual function research, receptor signaling, and central nervous system pathways.
The disclaimer language is research-clear: For research purposes only. Not for human consumption. Their catalog includes adjacent melanocortin-class compounds (Melanotan-2, Semax, Selank) for comparative research, plus newer compounds like MOTS-C and Retatrutide.
6. Canadian Peptides — Established Domestic Generalist
Site: canadianpeptides.ca
Catalog focus: Long-running domestic generalist with stable inventory across compound categories
Canadian Peptides has been one of the longer-running domain names in this space and carries PT-141 alongside the broader research peptide catalog. They market a 99%+ purity standard, lab-tested and COA verified, with fast shipping across Canada.
The product framing is research-clear with consistent disclaimer language. For researchers prioritizing vendor longevity over flashy marketing, particularly important when the compound is a cyclic heptapeptide where batch consistency over time matters for ongoing research, Canadian Peptides offers stability that newer entrants haven’t yet built up.
7. Clinical Peptides — Domestic Synthesis + Loyalty
Site: clinicalpeptides.net (also clinicalpeptides.ca)
Catalog focus: Canadian-synthesized peptides with rewards program economics
Clinical Peptides has leaned into Canadian-domestic synthesis with loyalty mechanics that make sense for repeat PT-141 buyers. Most of their peptides are now manufactured in Canada, synthesized, purified, and completed within Canada, with in-house synthesis and strict adherence to USP-grade excipient standards ensuring purity, consistency, and complete traceability.
The loyalty mechanics: for every $1 spent, customers earn 1 point, with every 100 points converting into a $5 discount toward future orders, plus a referral program offering 15% off for new customers and a $20 credit per successful referral. For ongoing PT-141 research procurement, the rewards compound meaningfully across an extended research program.
8. NCRP (National Canadian Research Peptides)
Site: ncrpcanada.com
Catalog focus: Manufacturer-direct sourcing with detailed handling guidance
NCRP is one of the more transparent manufacturer-direct operations in the Canadian market. All of their products are manufactured in Canada and certified greater than 98% pure by HPLC, with mass spectroscopy used to confirm sequence accuracy.
For PT-141 specifically, the mass spectroscopy confirmation matters more than for simpler peptides because confirming cyclic structure formation is part of what defines the compound. NCRP’s published handling guidance is also relevant: peptides should be stored in a dry, cool, dark place, with refrigeration at 4°C or colder away from bright light recommended for best preservation, and reconstituted only with bacteriostatic water using an insulin needle and gentle injection technique.
9. Amino Pure Canada — Format Flexibility
Site: aminopurecanada.ca
Catalog focus: Multiple administration formats (capsules, vials, atomizer sprays)
Amino Pure Canada offers research peptides across format options uncommon among Canadian suppliers, capsules, vials, and atomizer sprays. HPLC analysis and GMP manufacturing conditions back every batch at 99%+ purity with comprehensive Certificate of Analysis documentation.
For PT-141 specifically, the format options matter because PT-141 is one of the peptides where nasal spray administration has particular research relevance. The compound’s blood-brain barrier penetration profile makes intranasal delivery a research-meaningful comparison vs. injection administration. For researchers studying administration-route bioavailability differences in melanocortin pharmacology, the multi-format catalog is operationally valuable.
10. Purity Peptides — North American Sourcing Chain
Site: puritypeptides.ca
Catalog focus: North American-sourced research peptides with per-batch documentation
Purity Peptides sets itself apart with an explicit North American sourcing narrative, marketed as North American sourced and 3rd-party tested (not China), with verified COAs and purity reports on every product. For PT-141 specifically, the non-China sourcing positioning lines up with the under-dosing and substitution concerns that affect cyclic peptide imports.
For Canadian research labs working under institutional procurement requirements that mandate documented North American supply chains, Purity Peptides fits cleanly into that workflow. Their disclaimer language is research-clear: for laboratory research use only, not for human consumption.
11. VPeptide — Public Batch Verification
Site: vpeptide.com
Catalog focus: Research peptides with public Janoshik batch verification
VPeptide carries a research peptide catalog with the framing ultra-pure, lab-tested, and double-verified peptide quality, supplied for research purposes. The disclaimer language is appropriately cautious throughout the catalog.
VPeptide publishes per-batch testing references through Janoshik Analytical’s public testing system. For PT-141 buyers who treat verifiable lab links as a non-negotiable requirement, particularly given the cyclic peptide substitution risk, VPeptide’s verification infrastructure provides meaningful assurance.
12. PeptidePro Canada — Ontario-Based Dispatch
Site: peptideprocanada.com
Catalog focus: Focused catalog with central-Canada fulfillment speed
PeptidePro Canada offers a focused catalog with Ontario-based fulfillment. Products are typically supplied as lyophilized material in glass vials, shipped from Ontario, Canada, and provided strictly for non-clinical laboratory research by qualified facilities and trained personnel.
The Ontario-based fulfillment is a meaningful logistics advantage for researchers in central Canada. Toronto, Ottawa, and Montreal labs typically see same-province or next-province delivery times within 1-2 business days. Certificates of Analysis are published directly on product pages alongside detailed quality information rather than gated behind email requests.
📊 Side-by-Side: Canadian PT-141 Suppliers in 2026
| # | Supplier | Independent COA | Endotoxin Data | Cyclic Structure Verification | Differentiator |
|---|---|---|---|---|---|
| 1 | Nox Peptides | ✅ Public | ✅ Public | ✅ Mass spec confirmed | Purity + endotoxin transparency |
| 2 | Peptide Warehouse | ✅ | On request | ✅ | Made-in-Canada manufacturing |
| 3 | Polar Peptides | ✅ | On request | ✅ | Detailed product specs |
| 4 | Growth Guys | ✅ Janoshik | On request | ✅ | Public batch verification |
| 5 | XPeptides | ✅ | On request | ✅ | Canadian-domestic specialty |
| 6 | Canadian Peptides | ✅ | On request | ✅ | Long operating history |
| 7 | Clinical Peptides | ✅ | On request | ✅ | Loyalty rewards program |
| 8 | NCRP | ✅ | On request | ✅ | Manufacturer-direct |
| 9 | Amino Pure Canada | ✅ | On request | ✅ | Multi-format including nasal spray |
| 10 | Purity Peptides | ✅ Per-batch | On request | ✅ | North American sourcing |
| 11 | VPeptide | ✅ Janoshik | On request | ✅ | Public batch verification |
| 12 | PeptidePro Canada | ✅ Public on page | On request | ✅ | Ontario-based dispatch |
📊 PT-141 Pricing in Canada — 2026 Market Reality
| Vial Strength | Typical 2026 Canadian Range (CAD) | Per-Mg Range | Notes |
|---|---|---|---|
| 5mg | $45-$75 | ~$9-$15/mg | Common entry research format |
| 10mg | $50-$110 | ~$5-$11/mg | Standard research format with best per-mg economics |
| Nasal spray formats | $70-$130 | Variable based on concentration | Available from format-flexible suppliers like Amino Pure Canada |
The PT-141 Price Floor Warning
PT-141 typically runs $5-$15/mg (CAD) versus $1-$3/mg for simpler peptides like sermorelin. The synthesis complexity creates a real price floor: vials priced significantly below CAD $40 typically signal cut quality control corners or substituted compound. Common compromises at extreme discount pricing:
- Linear bremelanotide precursor sold as “PT-141” without proper cyclization
- Related melanocortin compounds (Melanotan-2, etc.) substituted for actual bremelanotide
- Underdosed product where the labeled weight is significantly higher than actual peptide content
- Imported raw material from facilities without quality verification infrastructure
The Vyleesi reference price (~USD $250 per autoinjector dose for the FDA-approved branded product in the US market) gives context for why research-grade pricing has structural support: even at premium research-grade pricing, the per-mg cost is dramatically below pharmaceutical pricing, making research-grade PT-141 economically rational rather than suspiciously cheap.
Storage, Handling & Reconstitution
| Stage | Protocol |
|---|---|
| Receipt | Inspect packaging integrity; verify tamper-evident seals; refrigerate immediately |
| Lyophilized storage (short-term) | 4°C refrigeration, away from light |
| Lyophilized storage (long-term) | -20°C freezer, away from light |
| Reconstitution diluent | Bacteriostatic water or sterile saline (per supplier-specific guidance) |
| Reconstitution technique | Inject diluent slowly down vial wall; gentle swirling, no aggressive shaking |
| Post-reconstitution storage | 2-8°C refrigerated; cyclic peptides like PT-141 generally hold stability well in solution |
| Disposal | Per municipal hazardous waste guidelines |
The cyclic structure makes PT-141 meaningfully more stable in solution than many linear peptides, one of the practical research advantages of the cyclized molecular design.
📚 Authority Sources for Canadian PT-141 Buyers
- 🇨🇦 Health Canada — Think twice before injecting peptides bought online (April 2026)
- 🇨🇦 Health Canada — Drug Product Database
- 📘 ResearchGate — PT-141: A Melanocortin Agonist Pharmacology Review
- 📘 PubMed — PT-141 Subjective Sexual Response Research (PMID: 14726972)
- 📰 CBC News — Health Canada warns against unauthorized peptides (April 2026)
- ⚕️ College of Physicians & Surgeons of Alberta — Unauthorized injectable peptides
- 🎓 McMaster University — Research-Only Peptides Q&A
- 🎓 McGill University Office for Science and Society
- 🏃 World Anti-Doping Agency — Prohibited List
Frequently Asked Questions
Is PT-141 legal to buy in Canada?
PT-141 (bremelanotide) sits in the research-chemical category in Canada in 2026. It isn’t approved as a prescription drug by Health Canada and doesn’t carry a Canadian Drug Identification Number (DIN). It can be purchased from Canadian domestic suppliers strictly for laboratory research use, not for human consumption. Cross-border purchases of FDA-approved Vyleesi from US prescriptions don’t translate to a Canadian regulatory pathway.
Why isn’t PT-141 approved in Canada when it’s approved in the US as Vyleesi?
FDA and Health Canada run independent regulatory review processes. Bremelanotide received FDA approval in 2019 as Vyleesi for premenopausal HSDD. The manufacturer hasn’t pursued or completed Health Canada approval for the Canadian market. Until Health Canada approval is granted, bremelanotide stays in the research-chemical category in Canada with no legal prescription pathway.
What’s the typical price for PT-141 in Canada?
Research-grade PT-141 in Canada typically runs CAD $50 to $110 per 10mg vial in 2026, with 5mg vials commonly available at CAD $45-$75. Nasal spray formats run higher at CAD $70-$130. The cyclic peptide synthesis complexity creates a real price floor, vials priced significantly below CAD $40 should be approached with skepticism.
Why is PT-141 more expensive per-mg than linear peptides like sermorelin?
Three structural reasons. First, the cyclic structure (Asp-Lys lactam bridge) requires controlled solid-phase synthesis with specific protecting-group strategy, linear analogs are 30-50% cheaper to manufacture. Second, the D-Phe substitution requires careful chiral purification, adding cost vs. all-L-amino acid peptides. Third, the FDA-approved Vyleesi reference pricing supports research-grade pricing levels above pure synthesis cost, a vendor selling PT-141 at sermorelin-like prices is likely substituting a cheaper compound.
How can I verify I’m getting genuinely cyclic PT-141 and not a linear precursor?
Mass spectrometry confirmation is the practical answer. The cyclic and linear forms have different molecular weights, mass spec on the final product confirms proper cyclization. Suppliers publishing per-batch mass spec data (like Nox Peptides and others publishing Janoshik-verified results) provide the verification infrastructure that protects against this substitution risk. Without mass spec confirmation, end-user verification of cyclization is essentially impossible.
Can I import Vyleesi from US prescriptions to Canada?
The regulatory situation is complex and varies by individual circumstance. Generally, Canadian residents cannot legally import prescription medications without specific Health Canada exemptions. Cross-border prescription purchases of Vyleesi for personal Canadian use exist in a regulatory grey zone with potential CBSA scrutiny. For researchers, the more straightforward pathway is sourcing research-grade PT-141 from Canadian domestic suppliers within the research-use framework.
What’s the difference between PT-141 and Melanotan-2?
Both are synthetic melanocortin receptor agonists derived from α-MSH, but with different receptor selectivity profiles and structural characteristics. Melanotan-2 has broader melanocortin receptor activity including MC1R (skin pigmentation), while PT-141 was specifically refined to favor MC3R/MC4R (CNS arousal pathways) without significant MC1R activity. They’re related compounds but research applications and pricing differ meaningfully.
Can I import PT-141 from US suppliers?
Importing PT-141 into Canada from international sources carries CBSA seizure risk that’s been at record-high enforcement levels in 2026. Beyond seizure risk, peptides held in non-climate-controlled customs warehouses can degrade, though cyclic peptides like PT-141 are generally more stable than linear peptides. Domestic Canadian sourcing cuts out customs risk entirely and supports faster shipping cycles.
What’s the WADA status of PT-141?
Melanocortin receptor agonists may be subject to World Anti-Doping Agency regulations. Athletes subject to WADA Code or any sport-governing-body anti-doping rules should consult their compliance officer for current prohibited substance status before sourcing or possessing any PT-141 compound.
Why is PT-141 sometimes called a “cyclic heptapeptide” in product descriptions?
The terminology is precise. “Cyclic” refers to the lactam bridge between Asp and Lys residues that closes the molecule into a ring structure. “Heptapeptide” refers to seven amino acids. So PT-141 is structurally a 7-amino-acid peptide cyclized via lactam bridge. The cyclic structure improves metabolic stability compared to linear peptide analogs in research settings, which is part of why pharmaceutical-grade development chose this molecular configuration over simpler linear melanocortin compounds.
⚖️ Legal Disclaimers
Research Use Only. All PT-141 (bremelanotide) products referenced in this article are sold and intended strictly for laboratory research and in vitro experimental use. They are not intended for human consumption, injection, ingestion, inhalation, topical application, or any other form of human use, nor for veterinary use, food, or cosmetic applications.
Not Approved by Health Canada. PT-141 (bremelanotide) is not approved as a drug by Health Canada. It does not carry a Canadian Drug Identification Number (DIN). It hasn’t been through the clinical safety and efficacy review required of authorized prescription medications in Canada. Authorized drugs for sale in Canada carry an 8-digit DIN on the label.
FDA-Approved Equivalent (Vyleesi) Not Available in Canada. Bremelanotide is FDA-approved in the United States as Vyleesi for premenopausal hypoactive sexual desire disorder (HSDD). However, this US approval doesn’t translate to Canadian regulatory authorization. Canadian residents seeking medical treatment for sexual dysfunction should consult licensed Canadian healthcare providers regarding Health Canada-approved alternatives.
Health Canada Public Advisory. Health Canada issued a public warning on April 10, 2026 against using unauthorized injectable peptide drugs purchased online, citing risks including hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots, growth of cancerous tumours, infections, allergic reactions, and interactions with other medications.
No Medical Advice. This article is published for educational and informational purposes only. It does not constitute medical advice, prescription guidance, diagnosis, or treatment recommendation. Anyone considering peptide-based therapies for personal health purposes should consult a licensed Canadian healthcare professional and obtain authorized prescription medications through a licensed Canadian pharmacy.
Anti-Doping Compliance. Melanocortin receptor agonists including PT-141 (bremelanotide) may be subject to World Anti-Doping Agency regulations or sport-governing-body anti-doping rules. Athletes subject to such regulations should consult their compliance officer before sourcing or possessing any PT-141 compound.
Pricing Information. Pricing ranges referenced in this article are approximate and reflect publicly observed Canadian market data as of publication. Actual prices vary by supplier, batch, vial strength, market conditions, and individual supplier operations. Pricing information is provided for general orientation only.
Cyclic Structure Substitution Risk. PT-141’s cyclic structure creates a documented risk of substitution with linear bremelanotide precursor or related melanocortin compounds at extreme discount pricing. Buyers are responsible for verifying the cyclic structure of any PT-141 product through independent third-party testing or supplier-published mass spectrometry documentation.
Limited Human Evidence. While bremelanotide has received FDA approval in the US for a specific indication, the broader research applications discussed in this article remain under investigation. Anecdotal reports and preclinical research data don’t constitute clinical proof of safety or efficacy for off-label or research applications.
Buyer Compliance. Buyers are solely responsible for compliance with all applicable federal, provincial, and municipal laws, regulations, and institutional policies in their jurisdiction, including Canada’s Food and Drugs Act, Controlled Drugs and Substances Act, Health Canada regulatory frameworks, and any institutional research ethics board (REB) requirements.
No Endorsement. The inclusion of any supplier in this guide reflects their public business activity in the Canadian research-use peptide market and does not constitute an endorsement, recommendation, or invitation to use PT-141 outside a controlled laboratory research setting.
No Liability. This publication, its authors, and Nox Peptides assume no liability for decisions made by readers based on the information provided herein. Sourcing decisions and any consequences thereof are the sole responsibility of the buyer.
The 2026 Bottom Line
Buying PT-141 in Canada in 2026 is structurally different from buying linear research peptides like BPC-157 or TB-500. The cyclic heptapeptide structure (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) plus D-Phe substitution creates synthesis complexity that establishes a real price floor, and the cyclic structure verification challenge means documentation depth, particularly mass spectrometry confirmation, matters more than for simpler peptides.
The unique regulatory dynamic: bremelanotide is FDA-approved in the US as Vyleesi but has no Health Canada equivalent. Canadian buyers face a binary, research-grade peptide retailers working under the research-use-only framing, or no legal pathway. The FDA approval doesn’t translate to Canadian prescription availability.
Nox Peptides sits at #1 on this list because the documentation depth, combined purity and endotoxin reporting per batch on a cyclic heptapeptide where structural verification matters, is currently unmatched in the Canadian retail peptide market. The remaining eleven suppliers each have legitimate strengths: Made-in-Canada manufacturing (Peptide Warehouse), detailed product specifications (Polar Peptides), Janoshik public verification (Growth Guys, VPeptide), Canadian-specialty positioning (XPeptides), vendor stability (Canadian Peptides), loyalty rewards (Clinical Peptides), manufacturer-direct (NCRP), multi-format including nasal spray (Amino Pure Canada), North American sourcing (Purity Peptides), and Ontario-based dispatch (PeptidePro Canada).
What no Canadian PT-141 buyer should compromise on in 2026: independent third-party COA verification with mass spectrometry confirmation of cyclic structure, domestic Canadian shipping, and clear research-use-only framing. For a cyclic heptapeptide where end-user structural verification is essentially impossible without analytical infrastructure, those three criteria aren’t optional, they’re the minimum baseline that protects against the documented substitution risk in the cyclic peptide market.
For researchers ready to source from the documentation leader, browse the PT-141 listing and per-batch lab reports at noxpeptides.ca.
Last updated: 2026. Pricing, regulatory information, and supplier details current as of publication date and subject to change. Consult Health Canada and the College of Physicians & Surgeons in your province for current guidance. All information provided for educational purposes only. Not medical advice.